Catequentinib
Catequentinib is a pharmaceutical drug for the treatment of cancer. It is approved in China for the treatment of locally advanced or metastatic non-small [cell lung cancer] in patients who have undergone progression or recurrence after at least two lines of systemic chemotherapy. It is also approved in China as a second‑line treatment for advanced soft-tissue sarcoma.
Catequentinib is a tyrosine kinase inhibitor that targets several different proteins including vascular [endothelial growth factor receptor], fibroblast [growth factor receptor], platelet-derived growth factor receptors, and c-kit.
Adverse effects include hypertension, fatigue, thyroid-stimulating hormone elevation, and hand-foot syndrome, among others.